Announcements Trials
Browse Landscape

Status

Completed 3Active not recruiting 2Unknown 1Terminated 1Recruiting 1Not yet recruiting 1

Sponsor Class

OTHER 1

Study Type

Observational 1

Sponsor

Cancer Type

Breast 1

Conditions

Melanoma 2Skin Neoplasms 1Sarcoma 1Prostatic Neoplasms 1Parkinson Disease 4, Autosomal Dominant Lewy Body 1Neoplasms 1Neoplasm Metastasis 1Multiple Myeloma 1Diabetes Mellitus, Insulin-Dependent, 12 1Cholangiocarcinoma 1Carcinoma, Transitional Cell 1Carcinoma, Renal Cell 1Carcinoma, Non-Small-Cell Lung 1Carcinoma, Merkel Cell 1Carcinoma, Hepatocellular 1Carcinoma, Basal Cell 1Breast Neoplasms 1Autoimmune Diseases 1

Interventions

Trastuzumab 77Capecitabine 59Cyclophosphamide 54Paclitaxel 51Docetaxel 49Letrozole 44Fulvestrant 43Lapatinib 34Doxorubicin 31Carboplatin 31Vinorelbine 30Bevacizumab 29Anastrozole 28pembrolizumab 25exemestane 24Tamoxifen 23Gemcitabine 22Radiotherapy 21Albumin-Bound Paclitaxel 19Everolimus 17Taxes 16Epirubicin 15Ado-Trastuzumab Emtansine 13130-nm albumin-bound paclitaxel 13pertuzumab 12palbociclib 12liposomal doxorubicin 11Magnetic Resonance Spectroscopy 11Filgrastim 11Cisplatin 11

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Terminated × Breast Neoplasms × Immunotherapy × Clear all
NCT06084676 2024-07-17

Organoid Model Predictive of Response to Immunotherapies

Indiana University

Terminated
1 enrolled
Breast

Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡